Teva’s Deferoxamine Mesylate treats iron intoxication and chronic iron overload due to transfusion-dependent anemia.
Teva Pharmaceutical Industries Ltd. (Nasdaq: TEVA; TASE: TEVA) announced today that the US Food and Drug Administration has granted approval for the company’s ANDA for Deferoxamine Mesylate for injection USP, 500 mg vial and 2 g vial. Shipment of this product will begin immediately.
Teva’s Deferoxamine Mesylate for injection is the AP-rated generic equivalent of Novartis’ Desferal for injection, a product indicated for acute treatment of iron intoxication and chronic iron overload due to transfusion-dependent anemias.
Teva stated that total annual sales of Deferoxamine Mesylate for injection are approximately $43 million.
Published by Globes [online], Israel business news - www.globes.co.il - on April 2, 2006
© Copyright of Globes Publisher Itonut (1983) Ltd. 2006